Status:

COMPLETED

Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma

Lead Sponsor:

University of Wisconsin, Madison

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Melanoma

Eligibility:

All Genders

18+ years

Brief Summary

This study uses molecular imaging and novel immune monitoring to identify a biomarker of response for melanoma patients receiving immunotherapy with anti-PD-1 immunotherapy. Prior to treatment, FDG an...

Eligibility Criteria

Inclusion

  • Participants must have a metastatic melanoma diagnosis (stage IV) for which treatment with nivolumab or pembrolizumab, either alone or in combination with other therapies, is planned. No additional laboratory testing is needed for the imaging in this study apart from the standard laboratory testing routinely obtained for treatment with nivolumab or pembrolizumab, either alone or in combination with other therapies.
  • Participants must have at least 2 subcutaneous or lymph node melanoma metastases that are 2 cm in greatest diameter and are amenable to being biopsied in clinic without requiring image-guidance.
  • Participants must be able to provide informed consent
  • Women of childbearing potential must be willing to use effective contraception as discussed with their oncologist while participating in this study.

Exclusion

  • Not able to receive treatment with either nivolumab or pembrolizumab.
  • Women of child-bearing potential must have a negative serum or urine pregnancy test within 7 days of the first study FLT PET/CT and must not be breast feeding for the duration of study participation.

Key Trial Info

Start Date :

November 2 2017

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

June 17 2022

Estimated Enrollment :

5 Patients enrolled

Trial Details

Trial ID

NCT03356470

Start Date

November 2 2017

End Date

June 17 2022

Last Update

July 11 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Wisconsin Carbone Cancer Center

Madison, Wisconsin, United States, 53792